| Enrolling By Invitation | Thera-Clean® Microbubbles System in Patients With Skin Diseases NCT07050810 | Northwestern University | EARLY_Phase 1 |
| Recruiting | Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa NCT06834035 | M. Peter Marinkovich | Phase 1 / Phase 2 |
| Recruiting | A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis NCT06917690 | Chiesi Farmaceutici S.p.A. | Phase 3 |
| Enrolling By Invitation | Reproductive Options in Inherited Skin Diseases NCT06330324 | Maastricht University Medical Center | — |
| Recruiting | Qualitative Study in Patients With Genodermatoses and Healthcare Professionals on Reproductive Counselling NCT06330350 | Maastricht University Medical Center | — |
| Active Not Recruiting | Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III) NCT05838092 | RHEACELL GmbH & Co. KG | Phase 3 |
| Active Not Recruiting | Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III, NCT05464381 | RHEACELL GmbH & Co. KG | Phase 3 |
| Active Not Recruiting | A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Trea NCT05725018 | Abeona Therapeutics, Inc | Phase 3 |
| Completed | Characterization of the Microbiome in Colonized Dystrophic and Junctional Epidermolysis Bullosa Wounds Before NCT05533866 | Northwestern University | EARLY_Phase 1 |
| Completed | Safety, Tolerability, and Pharmacokinetics of Ascending Topical Doses of TCP-25 Applied to Epidermal Suction B NCT05378997 | Xinnate AB | Phase 1 |
| Unknown | Dose-ranging Study of Dentoxol® Mouthrinse for Managing Oral Symptoms in People With Epidermolysis Bullosa. NCT05288478 | University of Chile | Phase 2 |
| Completed | Improve Adherence to Weak or Strong Opioid Analgesics at the Time of Care in Children With Hereditary Epidermo NCT04853667 | Assistance Publique - Hôpitaux de Paris | — |
| Unknown | The State of Sexual Development in Children With Inherited Epidermolysis Bullosa NCT05033574 | National Medical Research Center for Children's Health, Russian Federation | — |
| Completed | Topical Gentamicin Nonsense Suppression Therapy of EB NCT04644627 | Oslo University Hospital | Phase 1 / Phase 2 |
| Withdrawn | The Efficacy and Safety of 3% Cannabidiol (CBD) Cream in Patients With Epidermolysis Bullosa: A Phase II/III T NCT04613102 | Elena Pope | Phase 2 / Phase 3 |
| Withdrawn | A Pilot Study to Explore the Role of Gut Flora in Epidermolysis Bullosa NCT04213703 | ProgenaBiome | — |
| Completed | Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa ( NCT04227106 | Abeona Therapeutics, Inc | Phase 3 |
| Completed | Pregabalin Treatment for RDEB Pain and Itch NCT03928093 | The Hospital for Sick Children | Phase 3 |
| Completed | A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa NCT03836001 | Stanford University | Phase 2 |
| Completed | Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epi NCT03389308 | Castle Creek Pharmaceuticals, LLC | Phase 2 |
| Unknown | Computational Drug Repurposing for All EBS Cases NCT03269474 | Joyce Teng | — |
| Completed | Survey to Identify Burdens and Unmet Needs of Patients With Epidermolysis Bullosa NCT03158662 | Amicus Therapeutics | — |
| Completed | Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa NCT03068780 | Amryt Research Limited | Phase 3 |
| Completed | Evaluation of the Efficacy of ROPIVACAINE in Children and Young Adults With Hereditary Epidermolysis Bullosa NCT03730584 | Assistance Publique - Hôpitaux de Paris | N/A |
| Completed | Observational Study of a Cohort of Patients With Hereditary Epidermolysis Bullosa NCT04217538 | Centre Hospitalier Universitaire de Nice | — |
| Completed | Uses of Irradiated Human Amniotic Membrane in the Treatment of Dystrophic Epidermolysis Bullosa Patients NCT03942250 | Egyptian Atomic Energy Authority | N/A |
| Completed | Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients NCT02654483 | Jean Yuh Tang | Phase 2 |
| Completed | Topical BPM31510 3.0% Cream in Patients With Epidermolysis Bullosa NCT02793960 | Shasa Hu | Phase 1 |
| Completed | Study of Cellutome System for Treatment of Individual Lesions in EB Pts NCT02670837 | Masonic Cancer Center, University of Minnesota | N/A |
| Completed | MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs NCT02582775 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Terminated | Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermo NCT02670330 | Scioderm, Inc. | Phase 3 |
| Completed | ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa NCT02384460 | Scioderm, Inc. | Phase 3 |
| Terminated | Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa NCT02090283 | Scioderm, Inc. | Phase 2 |
| Completed | Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa NCT02014376 | Scioderm, Inc. | Phase 2 |
| Terminated | A Study of the Efficacy and Safety of ABH001 in the Treatment of Patients With Epidermolysis Bullosa Who Have NCT01749306 | Shire Regenerative Medicine, Inc. | Phase 3 |
| Completed | Treatment of Chronic and Non-Chronic Wounds in Patients With Recessive Dystrophic Epidermolysis Bullosa Using NCT01716169 | Stanford University | N/A |
| Terminated | A Observational Study to Evaluate Apligraf(R) in Nonhealing Wounds of Subjects With Epidermolysis Bullosa NCT01619670 | University Hospital, Basel, Switzerland | Phase 4 |
| Withdrawn | Grafting of Epidermolysis Bullosa Wounds Using Cultured Revertant Autologous Keratinocytes NCT01454687 | Stanford University | N/A |
| Unknown | Treatment of Dowling Maera Type of Epidermolysis Bullosa Simplex by Oral Erythromycin NCT01340235 | Centre Hospitalier Universitaire de Nice | Phase 3 |
| Completed | Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa NCT01263379 | Abeona Therapeutics, Inc | Phase 1 / Phase 2 |
| Completed | Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs NCT01033552 | Masonic Cancer Center, University of Minnesota | Phase 1 / Phase 2 |
| Terminated | Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB) NCT00881556 | Columbia University | EARLY_Phase 1 |
| Completed | Study of Alwextin® Cream in Treating Epidermolysis Bullosa NCT00825565 | Northwestern University | Phase 2 |
| Terminated | Allogeneic Hematopoietic Stem Cell Transplant For Epidermolysis Bullosa NCT00478244 | Masonic Cancer Center, University of Minnesota | N/A |
| Completed | Trial To Assess Efficacy Of A Chimeric Skin In Patients With Epidermolysys Bullosa NCT00987142 | Tigenix S.A.U. | Phase 2 |
| Completed | The Efficacy of Trimethoprim in Wound Healing of Patients With Epidermolysis Bullosa NCT00380640 | The Hospital for Sick Children | Phase 2 |
| Terminated | A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa NCT00311766 | RegeneRx Biopharmaceuticals, Inc. | Phase 2 |
| Completed | Phase I Study of Isotretinoin in Patients With Recessive Dystrophic Epidermolysis Bullosa NCT00014729 | University of North Carolina | Phase 1 |
| Completed | Study of the Nutritional, Metabolic, and Body Composition Profile in Children and Adolescents With Epidermolys NCT00004791 | National Center for Research Resources (NCRR) | — |
| Completed | Establishment of the National Epidermolysis Bullosa Registry NCT00004761 | National Center for Research Resources (NCRR) | — |
| Withdrawn | Study to Evaluate the Efficacy of Tetracycline in Epidermolysis Bullosa NCT00336154 | Rambam Health Care Campus | Phase 4 |